Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


17.10.2022

1 Ann Neurol
1 BMC Neurol
1 J Neural Transm (Vienna)
1 J Neurol Neurosurg Psychiatry
1 J Neuropsychol
2 Mov Disord
1 Nervenarzt
2 Neurobiol Dis
4 Neurology
2 Neurosci Lett
3 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Neurol

  1. SCHIRINZI T, Maftei D, Passali FM, Grillo P, et al
    Olfactory neuron Prokineticin-2 as a potential target in Parkinson's disease.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26526.
    PubMed         Abstract available


    BMC Neurol

  2. FAZLOLLAHI A, Zahmatyar M, Alizadeh H, Noori M, et al
    Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.
    BMC Neurol. 2022;22:383.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  3. KANEL P, Spears CC, Roytman S, Koeppe RA, et al
    Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis.
    J Neural Transm (Vienna). 2022 Oct 12. pii: 10.1007/s00702-022-02547.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  4. DRAZICH-TAYLOR EHS, Todd E, Convery R, Bocchetta M, et al
    Q351R MAPT mutation is associated with a mixed 3R/4R tauopathy and a slowly progressive cognitive, behavioural and parkinsonian syndrome.
    J Neurol Neurosurg Psychiatry. 2022 Oct 13. pii: jnnp-2022-329330.
    PubMed        


    J Neuropsychol

  5. READMAN MR, Crawford TJ, Linkenauger SA, Bek J, et al
    Motor imagery vividness and symptom severity in Parkinson's disease.
    J Neuropsychol. 2022 Oct 13. doi: 10.1111/jnp.12293.
    PubMed         Abstract available


    Mov Disord

  6. HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
    Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
    Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
    PubMed         Abstract available

  7. CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
    Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
    Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
    PubMed         Abstract available


    Nervenarzt

  8. JOST WH, Buhmann C, Classen J, Eggert K, et al
    [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Nervenarzt. 2022;93:1035-1045.
    PubMed         Abstract available


    Neurobiol Dis

  9. PUIGROS M, Calderon A, Perez-Soriano A, de Dios C, et al
    Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease.
    Neurobiol Dis. 2022;174:105885.
    PubMed         Abstract available

  10. RYU DW, Yoo SW, Oh YS, Lee KS, et al
    Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes.
    Neurobiol Dis. 2022;174:105883.
    PubMed         Abstract available


    Neurology

  11. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed         Abstract available

  12. KIM R, Lee TL, Lee H, Ko DK, et al
    Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease: A Meta-analysis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201453.
    PubMed         Abstract available

  13. BECKER S, Bode M, Brockmann K, Gasser T, et al
    Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201201.
    PubMed         Abstract available

  14. ZHANG Y, He X, Mo C, Liu X, et al
    Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201204.
    PubMed         Abstract available


    Neurosci Lett

  15. YU Z, Huang L, Xia Y, Cheng S, et al
    Analysis of the m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
    Neurosci Lett. 2022 Oct 6:136907. doi: 10.1016/j.neulet.2022.136907.
    PubMed         Abstract available

  16. ZHANG X, Wang S, Li X, Li X, et al
    Hemoglobin-binding alpha-synuclein levels in erythrocytes are elevated in patients with multiple system atrophy.
    Neurosci Lett. 2022;789:136868.
    PubMed         Abstract available


    PLoS One

  17. TORRADO JC, Husebo BS, Allore HG, Erdal A, et al
    Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson's disease: Protocol of the mixed method, cyclic ActiveAgeing study.
    PLoS One. 2022;17:e0275747.
    PubMed         Abstract available

  18. DE GOES MCR, Sarmento A, Lima I, Lyra M, et al
    After-effects of thixotropic conditionings on operational chest wall and compartmental volumes of patients with Parkinson's disease.
    PLoS One. 2022;17:e0275584.
    PubMed         Abstract available

  19. MIKOLAIZAK AS, Rochester L, Maetzler W, Sharrack B, et al
    Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol.
    PLoS One. 2022;17:e0269615.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. MORTEN MJ, Sirvio L, Rupawala H, Mee Hayes E, et al
    Quantitative super-resolution imaging of pathological aggregates reveals distinct toxicity profiles in different synucleinopathies.
    Proc Natl Acad Sci U S A. 2022;119:e2205591119.
    PubMed         Abstract available

  21. WANG X, Rimal S, Tantray I, Geng J, et al
    Prevention of ribosome collision-induced neuromuscular degeneration by SARS CoV-2-encoded Nsp1.
    Proc Natl Acad Sci U S A. 2022;119:e2202322119.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: